Claim Missing Document
Check
Articles

Found 38 Documents
Search

Coronavirus Disease 2019 in Chronic Kidney Disease: A Case Report Dela Hangri Jalmas; Fauzar Fauzar; Roza Kurniati; Deka Viotra; Harnavi Harun; Vesri Yoga; Alexander Kam
Jurnal Kesehatan Andalas Vol 10, No 2 (2021): Online July 2021
Publisher : Fakultas Kedokteran, Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/jka.v10i2.1718

Abstract

The COVID-19 pandemic has caused substantial morbidity and mortality worldwide. Older patients, male gender and those with preexisting comorbidities such as chronic kidney disease are reported to be more likely infected with SARS CoV-2 and are at higher risk of severe illness or death. It has been reported a 24 years old male was admitted to the hospital with shortness of breath, coughing, fever and paleness. The history of contact with confirmed COVID-19 cases was unclear. The patient works as a security officer. A history of hypertension is present. Laboratory results showed hemoglobin 7 g/dl, ureum 261 mg/dl, and creatinine 22,9 mg/dl. On the second day of admission, the patient experience increased shortness of breath, decreased consciousness and epistaxis. From the result of the nasopharyngeal swab, the patient tested positive for COVID-19 and was given Oseltamivir 75mg. The patient is prepared for hemodialysis, which was performed in the isolation room. After hemodialysis, the patient's condition improved with decreased shortness of breath and increased of consciousness. The patient comes out from the isolation room and discharges home in good condition. Antiviral therapy in CKD patients with Covid-19 infection requires dose adjustment. Immediate hemodialysis is required in patients with CKD and coexisting COVID-19 infection to improve the patient's condition. Prompt management for patients with CKD and COVID-19 will reduce the risk of mortality.Keywords:  COVID-19, chronic kidney disease, hemodialysis
Covid-19 in Lupus Nephritis Ramadhan Ananda Putra; Raveinal; Fauzar; Deka Viotra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 5 No. 7 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v5i7.336

Abstract

COVID-19 outbreak is currently being concerned for managing patients withimmunological disorders nowadays, including SLE. Lupus is a complexautoimmune disease characterized by the presence of autoantibodies that againstcell nucleus involved many organs in the body. Patients with SLE will increaserisk of severe infection because the intrinsic respond attack with their immunerespond though immunosuppressive drugs consumption, and will potentiallydamage some organs target associated with their disease. Lupus have multipleclinical manifestations with a fluctuating symptom. Patient who come with thesymptom ofbreathlessness will getworse day by day. The symptom could be felt inthe same time as fatigue, joint pain, hair loss, malar rash, oral ulcer, pleuraleffusion and swollen feet. There's a patient with antinuclear antibody positive foranti-smith and anti-Ro/SS-A. She was diagnosed with COVID-19, SLE withnephritis, haemolytic anemia, vasculitis and pleural effusions. The clinicalmanifestations of this patient indicate a COVID-19 with lupus nephritis that hassevere disease. She was being treated with methylprednisolone andhydroxychloroquine for SLE and azithromycin plus oseltamivir as a therapy forCOVID-19. The effect of hydroxychloroquine on SARS-CoV-2 was better seen inpatients with SLE who gotthe medication regularly. Patients went home after 24days of hospitalization after negative RT-PCR results and clinical improvement ofLES.
Covid-19 in Lupus Nephritis Ramadhan Ananda Putra; Raveinal; Fauzar; Deka Viotra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 5 No. 7 (2021): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v5i7.336

Abstract

COVID-19 outbreak is currently being concerned for managing patients withimmunological disorders nowadays, including SLE. Lupus is a complexautoimmune disease characterized by the presence of autoantibodies that againstcell nucleus involved many organs in the body. Patients with SLE will increaserisk of severe infection because the intrinsic respond attack with their immunerespond though immunosuppressive drugs consumption, and will potentiallydamage some organs target associated with their disease. Lupus have multipleclinical manifestations with a fluctuating symptom. Patient who come with thesymptom ofbreathlessness will getworse day by day. The symptom could be felt inthe same time as fatigue, joint pain, hair loss, malar rash, oral ulcer, pleuraleffusion and swollen feet. There's a patient with antinuclear antibody positive foranti-smith and anti-Ro/SS-A. She was diagnosed with COVID-19, SLE withnephritis, haemolytic anemia, vasculitis and pleural effusions. The clinicalmanifestations of this patient indicate a COVID-19 with lupus nephritis that hassevere disease. She was being treated with methylprednisolone andhydroxychloroquine for SLE and azithromycin plus oseltamivir as a therapy forCOVID-19. The effect of hydroxychloroquine on SARS-CoV-2 was better seen inpatients with SLE who gotthe medication regularly. Patients went home after 24days of hospitalization after negative RT-PCR results and clinical improvement ofLES.
The Role of Urinary Potassium Examination on the Progressivity of Chronic Kidney Disease: A Narrative Literature Review Rezki Sadeli; Harnavi Harun; Drajad Priyono; Deka Viotra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 12 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i12.636

Abstract

Kidneys play an important role in potassium homeostasis. The important role of the kidneys in maintaining potassium balance is reflected in the high level of potassium disturbances in patients with decreased kidney function, especially patients with severely decreased renal function and patients who have comorbidities, such as diabetes, hypertension, or heart failure. Chronic kidney disease is characterized by abnormalities of kidney structure or function that persist for more than 3 months, have many complex causes, and have a major impact on global health status. There are several methods to measure the amount of potassium intake consumed, including a food frequency questionnaire, dietary recall, temporary urine potassium examination, and 24-hour urine potassium examination. The standard gold measurement for evaluating urinary potassium excretion is through 24-hour urine collection. This literature review aims to describe the role of urinary potassium excretion in assessing the progression of chronic kidney disease.
The Role of Urinary Potassium Examination on the Progressivity of Chronic Kidney Disease: A Narrative Literature Review Rezki Sadeli; Harnavi Harun; Drajad Priyono; Deka Viotra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 6 No. 12 (2022): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v6i12.636

Abstract

Kidneys play an important role in potassium homeostasis. The important role of the kidneys in maintaining potassium balance is reflected in the high level of potassium disturbances in patients with decreased kidney function, especially patients with severely decreased renal function and patients who have comorbidities, such as diabetes, hypertension, or heart failure. Chronic kidney disease is characterized by abnormalities of kidney structure or function that persist for more than 3 months, have many complex causes, and have a major impact on global health status. There are several methods to measure the amount of potassium intake consumed, including a food frequency questionnaire, dietary recall, temporary urine potassium examination, and 24-hour urine potassium examination. The standard gold measurement for evaluating urinary potassium excretion is through 24-hour urine collection. This literature review aims to describe the role of urinary potassium excretion in assessing the progression of chronic kidney disease.
Plasma Galectin-3 Biomarkers in Chronic Kidney Disease Annesa Fadella; Harnavi Harun; Drajad Priyono; Deka Viotra
Indonesian Journal of Multidisciplinary Science Vol. 2 No. 5 (2023): Indonesian Journal of Multidisciplinary Science
Publisher : International Journal Labs

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1218.023 KB) | DOI: 10.55324/ijoms.v2i5.444

Abstract

Assessment of renal function is based on determination of serum creatinine and creatinine-based equations to assess GFR. However, this marker is not perfect or accurate, especially for longitudinal monitoring of kidney function in Chronic Kidney Disease (CKD patients). Decreased kidney function can be slowed or even anticipated with early detection, so as to avoid secondary complications. So it is important to find new biomarkers that can identify individuals at risk as early as possible. Plasma galectin-3 is a ?-galactoside-binding lectin expressed in monocytes, which plays an important role in inflammation, immunity, cancer, and is involved in the pathogenesis of atherosclerosis, diabetes, renal fibrosis and asthma. Higher galectin-3 levels were associated with reduced eGFR in a cross-sectional study. Galectin-3 is essential in various biological activities including cell growth, cell proliferation, differentiation, apoptosis, pre-mRNA splicing, transformation, angiogenesis, inflammation, fibrosis, fibrogenesis and host defense. Galectin-3 is a stable biomarker and is not associated with age, body mass index or sex. Galectin-3 is also useful for detecting the early stages of some diseases. Galectin-3 shows no circadian variation and increases slightly after exercise, returning to normal levels after 1-3 hours. Higher concentrations of galectin-3 may be associated with CKD development, indicating the potential for new mechanisms related to galectin-3 expression that may contribute to CKD development. Galectin-3 has also been reported to play an important role in renal interstitial fibrosis. Thus, galectin-3 inhibition may be a promising therapeutic strategy to prevent kidney disease progression.
The Role of Corticosteroids in the Management of Drug Allergy: A Narrative Literature Review Rivani Sintia Suratman; Rudy Afriant; Roza Mulyana; Saptino Miro; Deka Viotra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 2 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i2.773

Abstract

Drug allergy is an adverse drug reaction that occurs through an immune reaction that occurs through IgE or a rapid hypersensitivity reaction with various mechanisms and clinical presentations. One of the therapeutic modalities for drug allergies is corticosteroids. In allergic processes, corticosteroids can suppress the production and effects of humoral factors involved in the inflammatory response, inhibit the migration of leukocytes to sites of inflammation, and interfere with the function of endothelial cells, granulocytes, mast cells, and fibroblasts. This literature review aimed to describe the role of corticosteroids in the management of drug allergies. Corticosteroids are used very widely in the treatment of various allergic diseases because of their strong anti-inflammatory properties. Corticosteroids inhibit the synthesis of a number of cytokines, such as the interleukins IL-1 to IL-6, tumor necrosis factor-α (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF). In conclusion, corticosteroids are one of the therapeutic modalities in various manifestations of drug allergies. Every drug allergy gets the anti-inflammatory effects of corticosteroids with different choices, routes, and doses for each manifestation.
The Role of Corticosteroids in the Management of Drug Allergy: A Narrative Literature Review Rivani Sintia Suratman; Rudy Afriant; Roza Mulyana; Saptino Miro; Deka Viotra
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 2 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i2.773

Abstract

Drug allergy is an adverse drug reaction that occurs through an immune reaction that occurs through IgE or a rapid hypersensitivity reaction with various mechanisms and clinical presentations. One of the therapeutic modalities for drug allergies is corticosteroids. In allergic processes, corticosteroids can suppress the production and effects of humoral factors involved in the inflammatory response, inhibit the migration of leukocytes to sites of inflammation, and interfere with the function of endothelial cells, granulocytes, mast cells, and fibroblasts. This literature review aimed to describe the role of corticosteroids in the management of drug allergies. Corticosteroids are used very widely in the treatment of various allergic diseases because of their strong anti-inflammatory properties. Corticosteroids inhibit the synthesis of a number of cytokines, such as the interleukins IL-1 to IL-6, tumor necrosis factor-α (TNF-α), and granulocyte-macrophage colony-stimulating factor (GM-CSF). In conclusion, corticosteroids are one of the therapeutic modalities in various manifestations of drug allergies. Every drug allergy gets the anti-inflammatory effects of corticosteroids with different choices, routes, and doses for each manifestation.
Effect of Ramadan Fasting on DNA Repair, Immune System, Inflammation and Cognitive Function in Chronic Kidney Disease Patients: A Systematic Literature Review Drajad Priyono; Harnavi Harun; Deka Viotra; Zaki Mahmudi Dasril
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 4 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i4.809

Abstract

Background: There have been many studies that say Ramadan fasting has a positive effect on reducing BMI, blood sugar, inflammatory factors, and DNA Repair. However, there are still no guidelines for fasting in patients with chronic kidney disease (CKD) both nationally and internationally. This study aimed to conduct a review to explore the effects of Ramadan fasting against chronic kidney disease, specifically on DNA repair, Immune System, Inflammation, and Cognitive Function in patients with chronic kidney disease. Methods: This study is a systematic literature review (SLR) with sources obtained from various reputable journal databases such as PubMed, Cochrane Library, EBSCO, and Elsevier using relevant keywords. The selected articles have passed the inclusion and exclusion criteria. A total of 39 articles that discuss fasting were obtained from Ramadan in chronic kidney disease patients on metabolic response and inflammatory markers in the body. Results: Ramadan fasting has a positive effect on the response to anti-inflammatory, expression of protective genes, markers of kidney and liver function, protective proteome, and oxidative stress. Conclusion: Ramadan fasting may provide a short-term protective effect against levels of systemic inflammation.
Effect of Ramadan Fasting on DNA Repair, Immune System, Inflammation and Cognitive Function in Chronic Kidney Disease Patients: A Systematic Literature Review Drajad Priyono; Harnavi Harun; Deka Viotra; Zaki Mahmudi Dasril
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 7 No. 4 (2023): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v7i4.809

Abstract

Background: There have been many studies that say Ramadan fasting has a positive effect on reducing BMI, blood sugar, inflammatory factors, and DNA Repair. However, there are still no guidelines for fasting in patients with chronic kidney disease (CKD) both nationally and internationally. This study aimed to conduct a review to explore the effects of Ramadan fasting against chronic kidney disease, specifically on DNA repair, Immune System, Inflammation, and Cognitive Function in patients with chronic kidney disease. Methods: This study is a systematic literature review (SLR) with sources obtained from various reputable journal databases such as PubMed, Cochrane Library, EBSCO, and Elsevier using relevant keywords. The selected articles have passed the inclusion and exclusion criteria. A total of 39 articles that discuss fasting were obtained from Ramadan in chronic kidney disease patients on metabolic response and inflammatory markers in the body. Results: Ramadan fasting has a positive effect on the response to anti-inflammatory, expression of protective genes, markers of kidney and liver function, protective proteome, and oxidative stress. Conclusion: Ramadan fasting may provide a short-term protective effect against levels of systemic inflammation.